Our company has been selected for a research and development project under the "Unmet Therapeutics Challenge Technology Development" category of the "Infectious Disease Prevention and Treatment Technology Development Program," organized by the Ministry of Health and Welfare and administered by the Korea Health Industry Development Institute (KHIDI). This program is part of the "2022 First-Round Health and Medical Technology R&D Program," a national R&D initiative aimed at strengthening infectious disease response capabilities and securing therapeutics for unmet infectious diseases. Our company will carry out research on "Development of a Novel Non-invasive Tuberculosis Treatment Based on M207" from July 1, 2022 to December 31, 2024.